Learn About Vivera's Patents & Licensing - Vivera Pharmaceuticals Inc.

Focusing on the future growth of Vivera’s various divisions, the Company has filed a number of patent applications for new medical technologies and medical devices. Behind the development of each product is years of expertise, research, design and development focused on bringing the best solutions to market for patients and their providers.

In addition to its own patents, Vivera holds an exclusive global license for the patented and one-of-a-kind sublingual drug delivery system, TABMELT^®.

Utilizing the TABMELT^® platform, Vivera has begun to lay the groundwork for clinical research trials for a variety of indications with the goal to gain FDA approval via Investigational New Drug (IND) and/or New Drug Application (NDA) pathways to globally commercialize its finished pharmaceutical products.

Vivera's Patents

Country	Title	Status
United States	PHASED INFECTION TESTING METHOD AND APPARATUS	Pending
United States	INFECTION TESTING METHOD AND APPARATUS	Pending
United States	SELF-CONTAINED, PORTABLE, SANITIZATION DEVICE AND TELEMEDICINE STATION	Pending
United States	SECURE SMART DOSING SYSTEM WITH AUTOMATED DELIVERY, MEASUREMENT, AND MANAGEMENT	Granted, 2021
United States	SMART INHALER DEVICE WITH AUTOMATED DOSE DELIVERY, MEASUREMENT, AND MANAGEMENT	Granted, 2021

Licensed Patents

Country	Title	Status
Australia	All Natural, Non-Toxic Sublingual Drug Delivery Systems	Granted, 2016
Canada	All Natural, Non-Toxic Sublingual Drug Delivery Systems	Granted, 2018
Great Britain	All Natural, Non-Toxic Sublingual Drug Delivery Systems	Granted, 2018
Israel	All Natural, Non-Toxic Sublingual Drug Delivery Systems	Pending
Japan	All Natural, Non-Toxic Sublingual Drug Delivery Systems	Pending
Mexico	All Natural, Non-Toxic Sublingual Drug Delivery Systems	Pending
Russia	All Natural, Non-Toxic Sublingual Drug Delivery Systems	Granted, 2021
United States	All Natural, Non-Toxic Sublingual Drug Delivery Systems	Pending